LOGC vs ORGS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LOGC is a StrongBuy and ORGS is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LOGC’s FA Score shows that 0 FA rating(s) are green whileORGS’s FA Score has 1 green FA rating(s).
- LOGC’s FA Score: 0 green, 5 red.
- ORGS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LOGC’s TA Score shows that 6 TA indicator(s) are bullish while ORGS’s TA Score has 4 bullish TA indicator(s).
- LOGC’s TA Score: 6 bullish, 3 bearish.
- ORGS’s TA Score: 4 bullish, 3 bearish.
Price Growth
LOGC (@Internet Retail) experienced а +6.96% price change this week, while ORGS (@Biotechnology) price change was -57.93% for the same time period.
The average weekly price growth across all stocks in the @Internet Retail industry was +0.89%. For the same industry, the average monthly price growth was +14.04%, and the average quarterly price growth was +9.92%.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.
Reported Earning Dates
ORGS is expected to report earnings on Nov 08, 2024.
Industries' Descriptions
@Internet Retail (+0.89% weekly)The internet retail industry includes companies that sell products and services through the Internet. With more and more consumers using online retailers, the companies have seen a big increase in the use of their services. Some of the companies in the group are focused on selling business-to-business products and services. Others sell business-to-consumer products and services. Internet retailers offer a wide variety of products like books, apparel, and electronics. Some companies even specialize in only one or two categories. One potentially critical factor for players to thrive in this space is the quality and speed of product delivery. This requires an investment in efficient distribution networks. Things like logistics are important factors in the success in the extremely competitive industry. For a company to stay relevant in the industry it must have effective pricing strategies and upgraded websites. The websites must be easy to navigate and engaging for customers. In addition to the revenues generated from straight sales, internet retailers can generate revenue from subscription fees and advertising. Amazon.com, Inc., Alibaba Group, and JD.com are some of the global leaders.
@Biotechnology (+0.91% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| LOGC | ORGS | LOGC / ORGS | |
| Capitalization | 143M | 25.3M | 565% |
| EBITDA | -221M | -25.49M | 867% |
| Gain YTD | 5.882 | -75.634 | -8% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 156M | 662K | 23,565% |
| Total Cash | 150M | N/A | - |
| Total Debt | 0 | 13M | - |
LOGC | ORGS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 31 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 43 Fair valued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 44 | 98 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ORGS's Valuation (30) in the Biotechnology industry is in the same range as LOGC (43) in the Pharmaceuticals Major industry. This means that ORGS’s stock grew similarly to LOGC’s over the last 12 months.
ORGS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as LOGC (100) in the Pharmaceuticals Major industry. This means that ORGS’s stock grew similarly to LOGC’s over the last 12 months.
LOGC's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as ORGS (100) in the Biotechnology industry. This means that LOGC’s stock grew similarly to ORGS’s over the last 12 months.
LOGC's Price Growth Rating (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for ORGS (98) in the Biotechnology industry. This means that LOGC’s stock grew somewhat faster than ORGS’s over the last 12 months.
LOGC's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ORGS (100) in the Biotechnology industry. This means that LOGC’s stock grew similarly to ORGS’s over the last 12 months.
| LOGC | ORGS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 6 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 90% | 6 days ago 81% |
| Momentum ODDS (%) | 2 days ago 79% | N/A |
| MACD ODDS (%) | N/A | 6 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 79% | 6 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 76% | 6 days ago 90% |
| Advances ODDS (%) | 2 days ago 81% | 29 days ago 83% |
| Declines ODDS (%) | N/A | 6 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 87% | 6 days ago 82% |
| Aroon ODDS (%) | 2 days ago 83% | 6 days ago 89% |
LOGC and
Correlation & Price change
A.I.dvisor indicates that over the last year, LOGC has been closely correlated with EPIX. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if LOGC jumps, then EPIX could also see price increases.
| Ticker / NAME | Correlation To LOGC | 1D Price Change % | ||
|---|---|---|---|---|
| LOGC | 100% | +0.16% | ||
| EPIX - LOGC | 67% Closely correlated | -5.59% | ||
| TSHA - LOGC | 45% Loosely correlated | -3.40% | ||
| PCVX - LOGC | 45% Loosely correlated | -2.46% | ||
| ATNM - LOGC | 43% Loosely correlated | +3.30% | ||
| LGND - LOGC | 39% Loosely correlated | +0.10% | ||
More | ||||
ORGS and
Correlation & Price change
A.I.dvisor tells us that ORGS and LOGC have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ORGS and LOGC's prices will move in lockstep.
| Ticker / NAME | Correlation To ORGS | 1D Price Change % | ||
|---|---|---|---|---|
| ORGS | 100% | -42.18% | ||
| LOGC - ORGS | 29% Poorly correlated | +0.16% | ||
| KTRA - ORGS | 29% Poorly correlated | N/A | ||
| FATE - ORGS | 27% Poorly correlated | -1.24% | ||
| KMSTF - ORGS | 25% Poorly correlated | N/A | ||
| CRBU - ORGS | 24% Poorly correlated | -1.00% | ||
More | ||||